Evidence map›Paper›PMID 38855722›Full record

ArticleWellcome open research2023

Phenotypes associated with genetic determinants of type I interferon regulation in the UK Biobank: a protocol.

Bastien Rioux, Michael Chong, Rosie Walker, Sarah McGlasson, Kristiina Rannikmäe, Daniel McCartney, John McCabe, Robin Brown, Yanick J Crow, David Hunt and 1 more

Abstract read
In one paragraph

Article in Wellcome open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bastien RiouxCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.ORCID https://orcid.org/0000-0002-0292-259X
Michael ChongPopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Rosie WalkerDepartment of Psychology, University of Exeter, Exeter, England, UK.
Sarah McGlassonCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.
Kristiina RannikmäeCentre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, Scotland, UK.
Daniel McCartneyCentre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK.
John McCabeSchool of Medicine, University College Dublin, Dublin, Leinster, Ireland.
Robin BrownDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, England, UK.
Yanick J CrowMRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK.
David Hunt *Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.
William Whiteley *Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Background: Type I interferons are cytokines involved in innate immunity against viruses. Genetic disorders of type I interferon regulation are associated with a range of autoimmune and cerebrovascular phenotypes. Carriers of pathogenic variants involved in genetic disorders of type I interferons are generally considered asymptomatic. Preliminary data suggests, however, that genetically determined dysregulation of type I interferon responses is associated with autoimmunity, and may also be relevant to sporadic cerebrovascular disease and dementia. We aim to determine whether functional variants in genes involved in type I interferon regulation and signalling are associated with the risk of autoimmunity, stroke, and dementia in a population cohort. Methods: We will perform a hypothesis-driven candidate pathway association study of type I interferon-related genes using rare variants in the UK Biobank (UKB). We will manually curate type I interferon regulation and signalling genes from a literature review and Gene Ontology, followed by clinical and functional filtering. Variants of interest will be included based on pre-defined clinical relevance and functional annotations (using LOFTEE, M-CAP and a minor allele frequency <0.1%). The association of variants with 15 clinical and three neuroradiological phenotypes will be assessed with a rare variant genetic risk score and gene-level tests, using a Bonferroni-corrected p-value threshold from the number of genetic units and phenotypes tested. We will explore the association of significant genetic units with 196 additional health-related outcomes to help interpret their relevance and explore the clinical spectrum of genetic perturbations of type I interferon. Ethics and dissemination: The UKB has received ethical approval from the North West Multicentre Research Ethics Committee, and all participants provided written informed consent at recruitment. This research will be conducted using the UKB Resource under application number 93160. We expect to disseminate our results in a peer-reviewed journal and at an international cardiovascular conference.

Indexed as

dementiageneticsinflammationinterferonopathylupusstroketype I interferonUK Biobankvariants

Identifiers

PMID38855722
PMCPMC11162527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.